MedPath

Arava Bio-Tech Ltd.

🇮🇱Israel
Ownership
Holding
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds

Phase 2
Conditions
Other Ulcers Wounds and Skin Problems
Wounds
Interventions
Drug: Placebo
Drug: AR/101
First Posted Date
2016-07-20
Last Posted Date
2016-07-20
Lead Sponsor
Arava Bio Tech Ltd.
Target Recruit Count
60
Registration Number
NCT02839226
Locations
🇮🇱

Sourasky Medical Center, Tel Aviv, Israel

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

Phase 2
Conditions
Wounds and Injuries
Interventions
Drug: AR/101
Drug: Placebo
First Posted Date
2015-11-11
Last Posted Date
2016-07-19
Lead Sponsor
Arava Bio Tech Ltd.
Target Recruit Count
18
Registration Number
NCT02602184
Locations
🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.